TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,628 | -55.7% | 171,115 | -35.1% | 0.01% | -57.1% |
| Q1 2023 | $5,926 | +67.8% | 263,499 | +56.9% | 0.01% | +55.6% |
| Q4 2022 | $3,532 | -99.9% | 167,937 | +1.5% | 0.01% | -18.2% |
| Q3 2022 | $4,079,000 | +8.2% | 165,534 | +6.4% | 0.01% | +10.0% |
| Q2 2022 | $3,770,000 | -20.2% | 155,574 | -15.1% | 0.01% | +11.1% |
| Q1 2022 | $4,722,000 | -17.1% | 183,253 | -0.1% | 0.01% | -18.2% |
| Q4 2021 | $5,694,000 | -10.7% | 183,440 | -30.2% | 0.01% | -15.4% |
| Q3 2021 | $6,373,000 | +3.3% | 262,792 | +6.4% | 0.01% | -7.1% |
| Q1 2021 | $6,167,000 | +37.6% | 247,011 | +50.3% | 0.01% | +40.0% |
| Q4 2020 | $4,481,000 | – | 164,383 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |